Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases

References

• Gahrton G, Durie B, Samson D. Multiple myeloma and related disorders. Lancet Oncol. 2004;5(12):765.
   Google Scholar
• Devesa SS. Descriptive epidemiology of multiple myeloma. Berlin, Heidelberg: Springer; 1991.
   Google Scholar
• Greenlee MRT, Murray MT, Bolden MS, et al. Cancer statistics. Cancer J Clin. 2000;50(1):733. doi: 10.3322/canjclin.50.1.7
   Web of Science ®Google Scholar
• Vineis P. Incidence and time trends for lymphomas, leukemias and myelomas: hypothesis generation. Leukemia Res. 1996;20(4):285–290. doi: 10.1016/0145-2126(95)00153-0
   PubMed Web of Science ®Google Scholar
• Phekoo KJ, Schey SA, Richards MA, et al. A population study to define the incidence and survival of multiple myeloma in a national health service region in UK. Br J Haematol. 2004;127(3):299–304. doi: 10.1111/j.1365-2141.2004.05207.x
   PubMed Web of Science ®Google Scholar
• Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am. 1992;6(2):225–247.
   PubMed Web of Science ®Google Scholar
• Cartwright RA, Gilman EA, Gurney KA. Time trends in incidence of haematological malignancies and related conditions. Br J Haematol. 1999;106(2):281–295. doi: 10.1046/j.1365-2141.1999.01480.x
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance epidemiology and end results program. SEER stat fact sheets on multiple myeloma; 2013 [cited 2013 Apr 24]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Kim K, Lee JH, Kim JS, et al. Clinical profiles of multiple myeloma in Asia – an Asian myeloma network study. Am J Hematol. 2014;89(7):751–756. doi: 10.1002/ajh.23731
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee DS, Lee JJ, et al. Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean multiple myeloma working party. Int J Hematol. 2010;92(1):52–57. doi: 10.1007/s12185-010-0617-6
   PubMed Web of Science ®Google Scholar
• Huang SY, Yao M, Tang JL, et al. Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer. 2007;110(4):896–905. doi: 10.1002/cncr.22850
   PubMed Web of Science ®Google Scholar
• McKean-Cowdin R, Feigelson HS, Ross RK, et al. Declining cancer rates in the 1990s. J Clin Oncol. 2000;18(11):2258–2268. doi: 10.1200/JCO.2000.18.11.2258
   PubMed Web of Science ®Google Scholar
• Riccardi A, Gobbi PG, Ucci G, et al. Changing clinical presentation of multiple myeloma. Eur J Cancer. 1991;27(11):1401–1405. doi: 10.1016/0277-5379(91)90020-E
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi: 10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128. doi: 10.1038/leu.2013.313
   PubMed Web of Science ®Google Scholar
• Ludwig H, Durie BV, Turesson I, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111(8):4039–4047. doi: 10.1182/blood-2007-03-081018
   PubMed Web of Science ®Google Scholar
• Antonio P, Sara B, Maria-Victoria M, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report. Blood. 2015;125(13):2068–2074. doi: 10.1182/blood-2014-12-615187
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65(3):175–181. doi: 10.1034/j.1600-0609.2000.90221.x
   PubMed Web of Science ®Google Scholar
• Kleber M, Ihorst G, Deschler B, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. European J Haematol. 2009;83(6):519–527. doi: 10.1111/j.1600-0609.2009.01318.x
   PubMed Web of Science ®Google Scholar
• Augustson BM, Gulnaz B, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom medical research council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219–9226. doi: 10.1200/JCO.2005.03.2086
   PubMed Web of Science ®Google Scholar
• Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–277. doi: 10.1038/leu.2013.247
   PubMed Web of Science ®Google Scholar
• Bataille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment – a prospective study of 160 patients. Blood. 1984;63(2):468–476.
   PubMed Web of Science ®Google Scholar
• Durie BG, Stock-Novack D, Salmon SE, et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a southwest oncology group study. Blood. 1990;75(4):823–830.
   PubMed Web of Science ®Google Scholar
• Cuzick J, De Stavola BL, Cooper EH, et al. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. Br J Haematol. 1990;75(4):506–510. doi: 10.1111/j.1365-2141.1990.tb07790.x
   PubMed Web of Science ®Google Scholar
• Warren JL, Harlan LC, Stevens J, et al. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol. 2013;31(16):1984–1989. doi: 10.1200/JCO.2012.46.3323
   PubMed Web of Science ®Google Scholar
• Kiba T, Ito T, Nakashima T, et al. Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. BMC Cancer. 2014;14:78. doi: 10.1186/1471-2407-14-462
   PubMed Web of Science ®Google Scholar
• Gkotzamanidou M, Kastritis E, Nikitas N, et al. Increased serum lactate dehydrogenase should be included among the variables that define very-high-risk multiple myeloma. Clin Lymph Myelom Leuk. 2011;11(11):409–413. doi: 10.1016/j.clml.2011.07.001
   PubMed Web of Science ®Google Scholar